iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 582 participants.

Also called NCT05413369

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 582 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05413369
  • WHO UTN U1111-1267-2772
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05413369. Randomized; no masking; primary purpose treatment. Start 2022-07-07 (actual); primary completion 2023-10-20 (actual). Results posted on 2024-10-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Insulin glargine/Lixisenatide
Intervention (Drug)
IDegAsp
Intervention (Drug)
Metformin
Intervention (Drug)
SGLT2 inhibitor
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct05413369
Content hash
3659f17a7d7e33f1a0d47a4ed0448dcdbb03a8d457ac837626ca024c1b9d748f